WELCOME TO The HEALTHCARE REPORT
Newsletter | Member Login | Signup
Home > Companies > PeraHealth, Inc
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Health Technology
Microbot Medical | December 28, 2021
Microbot Medical Inc.announced that it has entered into a strategic collaboration agreement with Stryker, a leading global medical technology company. The company will collaborate with Stryker’s Neurovascular division to integrate its neurovascular instruments with Microbot’s LIBERTY Robotic System to develop the world’s first dedicated robotic procedural kits for use in certain neurovascular procedures. “We have already ensured that the L...
HIT Consultant | January 22, 2020
The New Year often brings with it an essence of transformation. This year, U.S. healthcare’s metamorphosis is now more than a decade old, as it continues to shed its antiquated legacy systems and siloes to embrace a different kind of entity-one that hopes to establish weight in value-based care at a scale robust enough to substantiate it. Healthcare providers are aiming to achieve that life cycle through a series of partnerships as well as mergers and acquisitions, which have become increa...
Digital Healthcare, Medical Devices
Prnewswire | May 10, 2023
Gaylord Specialty Healthcare, a nonprofit rehabilitation-focused healthcare system, is proud to announce that it is the first healthcare organization in the nation to use the Phagenyx® Neurostimulation System from Phagenesis, Ltd. to treat dysphagia among stroke patients. Dysphagia – or the difficulty or inability to swallow – affects millions worldwide and is a common diagnosis among adult patients at long-term acute care hospitals, including Gaylord Hospital. D...
Novartis Pharma AG | September 19, 2022
Sandoz, a global leader in off-patent medicines, announces further progress on its biosimilar pipeline, with the release of positive results from the integrated ROSALIA Phase I/III clinical trial study for its proposed biosimilar denosumab. “Biosimilars have the opportunity to create a substantial positive impact on patient access and healthcare systems sustainability. Therefore, this important milestone means that we are one step closer to giving individ...
Medical Devices
Video
DATA ARCHITECTURE
Whitepaper
Future of Healthcare
Article
Digital Healthcare
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE